SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance
I. Kimura, Y. Kosugi, J. Wu, D. Yamasoba, E. P. Butlertanaka, Y. L. Tanaka, Y. Liu, K. Shirakawa, Y. Kazuma, R. Nomura, Y. Horisawa, K. Tokunaga, A. Takaori-Kondo, H. Arase, The Genotype to Phenotype Japan (G2P-Japan) Consortium, A. Saito, S. Nakagawa, K. Sato
Abstract
SARS-CoV-2 Lambda, a new variant of interest, is now spreading in some South American countries; however, its virological features and evolutionary trait remain unknown. Here we reveal that the spike protein of the Lambda variant is more infectious and it is attributed to the T76I and L452Q mutations. The RSYLTPGD246-253N mutation, a unique 7-amino-acid deletion mutation in the N-terminal domain of the Lambda spike protein, is responsible for evasion from neutralizing antibodies. Since the Lambda variant has dominantly spread according to the increasing frequency of the isolates harboring the RSYLTPGD246-253N mutation, our data suggest that the insertion of the RSYLTPGD246-253N mutation is closely associated with the massive infection spread of the Lambda variant in South America. HighlightsO_LILambda S is highly infectious and T76I and L452Q are responsible for this property C_LIO_LILambda S is more susceptible to an infection-enhancing antibody C_LIO_LIRSYLTPGD246-253N, L452Q and F490S confer resistance to antiviral immunity C_LI Graphical Abstract O_FIG_DISPLAY_L [Figure 1] M_FIG_DISPLAY C_FIG_DISPLAY
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- SARS-CoV-2 Lambda Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies and Convalescent Serum
T. Tada, H. Zhou, … N. R. Landau·bioRxiv·Jul 2, 2021
- Cutting epitopes to survive: the case of lambda variant
Stefano Pascarella, Massimo Ciccozzi, … Antonio Cassone·bioRxiv·Aug 14, 2021
- The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccines
- The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines
- An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity
C. Motozono, M. Toyoda, … K. Sato·bioRxiv·Apr 2, 2021
- The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies.
T. Tada, H. Zhou, … N. R. Landau·bioRxiv·May 14, 2021